The ANP32A Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma line, featuring targeted disruption of the ANP32A gene. This product provides a mixed clonal pool that preserves genetic heterogeneity while enabling robust loss-of-function analysis, making it well-suited for pooled assays, functional screens, and studies requiring bulk cell populations.
HT29 is a well-characterized human colorectal adenocarcinoma cell line established from a 44-year-old female and exhibits epithelial morphology. It serves as a key model for colon carcinoma research, particularly for investigating signaling pathways, apoptosis regulation, and drug response mechanisms. The cell line??s retention of functional apoptotic machinery and chromatin regulatory networks makes it an appropriate host for interrogating ANP32A-dependent processes.
ANP32A encodes an acidic leucine-rich nuclear phosphoprotein that functions as a histone chaperone, facilitating histone exchange and nucleosome assembly to regulate chromatin dynamics. In the apoptosis pathway, ANP32A is activated downstream of caspases and directly promotes caspase-9 activation within the apoptosome, linking it to mitochondrial outer membrane permeabilization and cell death execution. The protein is phosphorylated by CK2, regulated by E2F transcription factors and DNA damage signals, and interacts with SET, importin-??, histones, and PP2A. Through these interactions, ANP32A influences MAPK and Wnt signaling cascades, modulates ATF2 activity, and controls gene expression programs critical for proliferation and survival.
In the HT29 colorectal cancer context, ANP32A knockout allows precise dissection of its contribution to tumor cell survival, chromatin state, and therapeutic response. ANP32A dysregulation is implicated in colorectal cancer progression and chemoresistance, and the polyclonal knockout model enables examination of how its absence affects apoptotic priming, histone modification landscapes, and signaling through oncogenic MAPK/Wnt pathways. Using polyclonal populations captures clonal variation in phenotype, offering a more realistic representation of tumor heterogeneity and pathway dependency.
Research applications include apoptosis analysis via caspase-3/7 assays, chromatin immunoprecipitation (ChIP-qPCR) for histone marks, co-immunoprecipitation of ANP32A with SET and caspase-9, and cell viability or migration/invasion assays to assess metastatic behavior. The cells are also suitable for drug sensitivity screens and transcriptomic profiling by RT-qPCR or RNA-seq to identify downstream targets. For additional details or to discuss project-specific uses, please contact Ascent Research.
